X. de Lamballerie

This study shows Sotrovimab remains effective against SARS-CoV-2 BQ.1.1 in a non-human primate model, as measured by reduced viral replication.

This study evaluates Sotrovimab's antiviral activity against BQ.1.1 and XBB.1 Omicron variants in a hamster model, finding retained but reduced efficacy compared to earlier variants.

This study evaluates the neutralizing activity of monoclonal antibodies against SARS-CoV-2 Omicron sub-lineages and finds reduced efficacy against several variants.

This study identifies a ten-protein diagnostic signature for Japanese encephalitis virus infection in cerebrospinal fluid with >99% accuracy using proteomics and machine learning.

This paper identifies biosynthetic proteins (Reps) that bind the SARS-CoV-2 spike RBD and neutralize the virus, including variants, with high potency and stability.

The paper evaluates the neutralizing activity of eight therapeutic antibodies against an Omicron SARS-CoV-2 isolate and finds significant loss of efficacy for most, with only Sotrovimab showing minimal reduction.

This study evaluates nitazoxanide's antiviral activity against SARS-CoV-2 in vitro and in vivo, finding that its standard dosage is ineffective due to insufficient drug concentration in target organs.

This study shows niclosamide is effective against SARS-CoV-2 and its variants in a human airway model, supporting its potential as a COVID-19 therapy.

This study compares the SARS-CoV-2 Alpha variant and G614 strain in Syrian hamsters, finding similar replication and disease outcomes but a slight fitness advantage for G614.

This study compares the replication efficiency of the SARS-CoV-2 20I/501Y.V1 variant with an ancestral strain in human bronchial epithelium models, finding the variant outcompetes the ancestral strain in competition experiments.

This study evaluates Imatinib's antiviral potential against SARS-CoV-2 in vitro and in vivo, finding it ineffective in key models despite plasma and lung concentrations.

This study adapts DENV-1 to Ae. albopictus mosquitoes through in vivo selection, identifying adaptive mutations that enhance infectivity but show limited individual transmission efficiency.

This study evaluates favipiravir's antiviral efficacy against SARS-CoV-2 in a Syrian hamster model, showing dose-dependent reduction of viral titers and disease symptoms.

The paper evaluates heating and chemical protocols for inactivating SARS-CoV-2, finding that Triton-X100 in guanidinium thiocyanate buffers achieves 6-log reduction, while heating protocols affect RNA detection.

This study screens an FDA-approved chemical library to identify potential inhibitors of SARS-CoV-2 replication in vitro, finding several compounds with antiviral potency.

This paper establishes a dengue virus panel representing all genotypes to aid in antiviral drug discovery, showing varying compound efficacies across genotypes.

This paper identifies an E460D substitution in TBEV RdRp that confers resistance to Galidesivir and attenuates the virus in mice.

This paper develops a chimeric Zika virus vaccine using a yellow fever 17-D backbone and shows it induces neutralizing antibodies and protects mice against ZIKV challenge.

This study re-encodes the Yellow Fever Virus genome with synonymous mutations to create attenuated strains, finding that certain mutations reduce virulence without significantly affecting replication fitness.

This study identifies key mutations in Yellow Fever Virus that enhance virulence in Syrian Golden Hamsters by analyzing their effects on disease symptoms and replication.